Interview with Bingshen Li, CEO, SinoGenoMax
SinoGenoMax was founded in 1998 with the purpose of participating in the Human Genome Project. Could you give us an overview of the company’s activities since then and the transformation…
Address: No. 3-707 North Yongchang Road,BDA,Beijing 100176,P.R.China.,China
Tel: +86 10 6788 3332
Web: http://www.sinogenomax.com/en
As one of the largest genomics-based biotech companies in China, SinoGenoMax Co.,Ltd. was incorporated in September 1998 by a joint investment from the Beijing Municipal Science & Technology Commission and Beijing Boda Sci-Tech Venture Capital Ltd. Its founding members include the Chinese Academy of Medical Sciences, Peking University, the Chinese Academy of Science, and the Beijing Institute of Medical Sciences. The affililated institute, Chinese National Human Genome Center of Beijing (CHGB) was established in October 1998 at SinoGenoMax.
SinoGenoMax participated in the International Human Genome Sequencing Project, and has been closely involved in several major genome-related research projects such as pathogenic microorganism sequencing projects, Chinese population single nucleotide polymorphism (SNP) genotyping project, and other disease genome research projects.
Originally focused on DNA sequencing and analysis, SinoGenoMax has subsequently expanded its expertise in all aspects of molecular biology and protein biology. SinoGenoMax has built up several independent technical groups including genomics group, proteomics group, and molecular biology group. In particular, SinoGenoMax has perfected a rigorous quality-management system to implement process monitoring and quality control for all the procedures we perform. SinoGenoMax has passed the ISO 9001:2000 international certification of quality management system since 2004, and is now preparing to obtain ISO/IEC 17025:2005 accreditation of testing laboratory.
There are currently 100 employees working at SinoGenoMax located in Beijing Economic-Technological Development Area. SinoGenoMax’s 5,000 square meter laboratory building is fully equipped with top class facilities including DNA Sequencers, mass spectrometry, HPLC, Microarray Chip Reader, and lab automation workstation, for high throughput operation and analysis in genomics and proteomics research. A proprietary Laboratory Information Management System(LIMS) has been implemented for standardized management of samples,data and work flow, and all procedures are performed under the guidance of corresponding SOPs.
In the past few years, SinoGenoMax has successfully provided high quality and cost-effective services for several international pharmaceutical companies. Whether in the scientific research or industrial of production, the widely recognized achievements have enabled SinoGenoMax to become the best biotechnology service company at home and abroad.
Large-scale DNA sequencing, Bioinformatics, Protein expression & Purification, Protein Seperation & Identification, Antibody Production, Functional Genomics & Drug Disc. Platform, Genome-Based Target Validation, Pathway-Based Target Validation, siRNA-Based Drug Screening
SinoGenoMax was founded in 1998 with the purpose of participating in the Human Genome Project. Could you give us an overview of the company’s activities since then and the transformation…
Harvest Integrated Research Organization (HiRO) is a CRO that serves both Asian biotechs looking to do clinical trials outside of the region, and US and European clients wanting to conduct…
A roundup of some of the biggest news stories from the pharma industry in China including Aspen’s purchase of Sandoz’s Chinese business; Moderna’s first mRNA facility in China; WuXi Biologics’…
A roundup of some of the latest news from Chinese pharma including CanSino’s Gates Foundation grant for polio vaccine R&D; Merck’s deal with Jiangsu Hengrui; the license agreement between GSK…
After four years away, Brendan Shaw recently returned to China to attend the ChinaBio Innovation and Investment Conference in Suzhou. Although geopolitical tensions, the fallout from COVID-19, and local market…
A roundup of some of the latest pharma news from China including Pfizer’s first Asia launch of Rimegepant migraine treatment in Hong Kong; Zhifei and GSK’s shingles vaccine deal, and…
A decade on from its launch, the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) initiative has made some significant wins but remains some way from fulfilling the vision of a fully…
Writing in the September 2023 edition of DIA’s Global Forum magazine, Shuting Li of Anhui Jimin Cancer Hospital and Xinfang Fan of Bayer Health Care Ltd. examine how Chinese clinical…
Ongoing geopolitical tensions between China and the West have led the G7 group of countries to warn of the threat of “economic coercion” from China and the US to scrutinise…
A roundup of some of the latest healthcare and pharma news from China including a crackdown on healthcare corruption; AstraZeneca’s cardiovascular mortality drug approval and mRNA manufacturing deal with CanSino;…
Writing in the August edition of DIA’s Global Forum magazine, Wen Yin of the Pfizer China R&D Center and Wanhe Deng of GSK China Investment look back on four years…
At a time when the country’s economy has fallen into a slump with the currency sinking to its lowest level in 16 years, Chinese giant Fosun Pharma continues to agressively…
A roundup of some of the biggest recent stories coming out of China, including the commerce minister’s peace offering to international drug companies; CSPC Pharmaceutical Group’s partnership with Pfizer; Merck’s…
See our Cookie Privacy Policy Here